Ignite Creation Date:
2024-05-05 @ 6:39 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00520390
Status:
COMPLETED
Last Update Posted:
2010-04-02
First Post:
2007-08-23
Brief Title:
A Phase I Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma EZN-2208-02
Sponsor:
Enzon Pharmaceuticals Inc
Organization:
Enzon Pharmaceuticals Inc
Study Overview
Official Title:
A Phase I Multicenter Open-Label Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38 Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Ymphoma EZN-2208-02
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma The safety of the study drug and its effect on the disease will also be studied
Enzon will also perform pharmacokinetic PK testing of EZN-2208 PK testing measures the amount of a drug in the body at different time points
Enzon will also perform pharmacokinetic PK testing of EZN-2208 PK testing measures the amount of a drug in the body at different time points
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None